IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma

Ibrain Pub Date : 2024-03-11 DOI:10.1002/ibra.12150
Ning Li, Limei Deng, Yuming Zhang, Xilian Tang, Bingxi Lei, Qingyu Zhang
{"title":"IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma","authors":"Ning Li,&nbsp;Limei Deng,&nbsp;Yuming Zhang,&nbsp;Xilian Tang,&nbsp;Bingxi Lei,&nbsp;Qingyu Zhang","doi":"10.1002/ibra.12150","DOIUrl":null,"url":null,"abstract":"<p>Glioma, a malignant brain tumor originating from neural glial cells, presents significant treatment challenges. However, the underlying mechanisms of glioma development are not fully understood, and effective targets are lacking. This study provides insights into the role of insulin-like growth factor 2 messenger RNA-binding protein 2 (IGF2BP2) in glioma progression and its therapeutic potential. Our analysis illustrated that elevated IGF2BP2 expression associated with significantly shorter survival among patients with low-grade glioma (LGG) in The Cancer Genome Atlas (TCGA) database. IGF2BP2 depletion led to compromised cell viability, G0/G1 phase arrest, and reduced colony-formation ability. Furthermore, ultrastructural analysis and mCherry-GFP-LC3 reporter assay revealed an increased abundance of autophagosomes upon IGF2BP2 knockdown. Western blot analysis corroborated these findings by showing reduced p62 levels coupled with increased LC3-ІІ/LC3-I ratio upon IGF2BP2 knockdown. A multicolor immunohistochemistry assay demonstrated the positive correlation between IGF2BP2 and p62 expression in glioma patient samples. Additionally, our analysis suggested a link between IGF2BP2 expression and drug-resistant markers in TCGA-LGG samples, and Cell Counting Kit-8 cell viability assay revealed that knockdown of IGF2BP2 sensitized cells to temozolomide treatment. This comprehensive exploration unveils the role of IGF2BP2 in glioma progression, shedding light on autophagy modulation and chemosensitization strategies for glioma therapy.</p>","PeriodicalId":94030,"journal":{"name":"Ibrain","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ibra.12150","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ibrain","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ibra.12150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Glioma, a malignant brain tumor originating from neural glial cells, presents significant treatment challenges. However, the underlying mechanisms of glioma development are not fully understood, and effective targets are lacking. This study provides insights into the role of insulin-like growth factor 2 messenger RNA-binding protein 2 (IGF2BP2) in glioma progression and its therapeutic potential. Our analysis illustrated that elevated IGF2BP2 expression associated with significantly shorter survival among patients with low-grade glioma (LGG) in The Cancer Genome Atlas (TCGA) database. IGF2BP2 depletion led to compromised cell viability, G0/G1 phase arrest, and reduced colony-formation ability. Furthermore, ultrastructural analysis and mCherry-GFP-LC3 reporter assay revealed an increased abundance of autophagosomes upon IGF2BP2 knockdown. Western blot analysis corroborated these findings by showing reduced p62 levels coupled with increased LC3-ІІ/LC3-I ratio upon IGF2BP2 knockdown. A multicolor immunohistochemistry assay demonstrated the positive correlation between IGF2BP2 and p62 expression in glioma patient samples. Additionally, our analysis suggested a link between IGF2BP2 expression and drug-resistant markers in TCGA-LGG samples, and Cell Counting Kit-8 cell viability assay revealed that knockdown of IGF2BP2 sensitized cells to temozolomide treatment. This comprehensive exploration unveils the role of IGF2BP2 in glioma progression, shedding light on autophagy modulation and chemosensitization strategies for glioma therapy.

Abstract Image

IGF2BP2 可调节自噬,是胶质瘤的预后标志物
胶质瘤是一种源自神经胶质细胞的恶性脑肿瘤,给治疗带来了巨大挑战。然而,胶质瘤发展的内在机制尚未完全明了,也缺乏有效的靶点。本研究深入探讨了胰岛素样生长因子2信使RNA结合蛋白2(IGF2BP2)在胶质瘤发展过程中的作用及其治疗潜力。我们的分析表明,在癌症基因组图谱(TCGA)数据库中,IGF2BP2表达升高与低级别胶质瘤(LGG)患者的生存期明显缩短有关。IGF2BP2消耗会导致细胞活力受损、G0/G1期停滞和集落形成能力下降。此外,超微结构分析和mCherry-GFP-LC3报告检测显示,IGF2BP2敲除后自噬体的丰度增加。Western 印迹分析证实了这些发现,显示 IGF2BP2 敲除后 p62 水平降低,LC3-ІІ/LC3-I 比率增加。多色免疫组化分析表明,在胶质瘤患者样本中,IGF2BP2 和 p62 的表达呈正相关。此外,我们的分析表明,在TCGA-LGG样本中,IGF2BP2的表达与耐药标记物之间存在联系,细胞计数试剂盒-8细胞活力测定显示,敲除IGF2BP2可使细胞对替莫唑胺治疗敏感。这一全面探索揭示了IGF2BP2在胶质瘤进展中的作用,为胶质瘤治疗中的自噬调节和化疗增敏策略提供了启示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信